GEMTESA has a proven safety and tolerability profile in patients with overactive bladder1,2

Patient having a conversation. GEMTESA® has a proven safety and tolerability profile in patients with overactive bladder.

GEMTESA adverse reactions compared to placebo1

Reported in 2% of patients treated with GEMTESA 75 mg for up to 12 weeks1,2

  GEMTESA
n (%)
PLACEBO
n (%)
NUMBER OF PATIENTS 545 540
HEADACHE 22 (4.0) 13 (2.4)
NASOPHARYNGITIS 15 (2.8) 9 (1.7)
DIARRHEA 12 (2.2) 6 (1.1)
NAUSEA 12 (2.2) 6 (1.1)
UPPER RESPIRATORY TRACT INFECTION 11 (2.0) 4 (0.7)
Heart and meter icon.

The first and only beta-3 agonist without a blood pressure warning in its label1,2

In a 4-week, randomized, placebo-controlled, ambulatory blood pressure study in OAB patients (n=200), daily treatment with GEMTESA 75 mg was not associated with clinically significant changes in blood pressure. Subjects enrolled in this study had a mean age of 59 years and 75% were female. Thirty-five percent of subjects had preexisting hypertension at baseline and 29% of all subjects were taking at least 1 concomitant antihypertensive medication.1

The first and only beta-3 agonist with no significant impact on blood pressure1,2

Hypertension and increased BP rates for GEMTESA compared with placebo for up to 12 weeks2

  GEMTESA
n (%)
PLACEBO
n (%)
NUMBER OF PATIENTS 545 540
HYPERTENSION 9 (1.7) 9 (1.7)
BP INCREASE 4 (0.7) 5 (0.9)

BP=blood pressure.

Schedule a live or virtual visit with a
GEMTESA representative
Request a rep
Doctor prepared to discuss GEMTESA and OAB with patients.
 

References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Data on file. Urovant Sciences GmbH.